In renal cell carcinoma, increased STAT3 activation is associated with increased metastasis and worse survival outcomes, but clinical trials targeting the STAT3 signaling pathway have shown varying levels of success in different RCC subtypes. This evidence concerns the gene STAT3 and hereditary clear cell renal cell carcinoma.